Study identifier:D2213C00001
ClinicalTrials.gov identifier:NCT02347176
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase 2b, Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Tralokinumab in Adult Subjects with Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis
Phase 2
No
-
All
204
Interventional
18 Years - 75 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Apr 2018 by MedImmune, LLC
MedImmune, LLC
-
The aim of the study is to evaluate the efficacy and safety of tralokinumab in adults with atopic dermatitis
Location
Location
Worcester, MA, United States, 01605
Location
Miami, FL, United States, 33144
Location
Houston, TX, United States, 77004
Location
Charleston, SC, United States, 29414
Location
Pflugerville, TX, United States, 78660
Location
Fremont, CA, United States, 94538
Location
Houston, TX, United States, 77056
Location
San Antonio, TX, United States, 78229
Arms | Assigned Interventions |
---|---|
Placebo Comparator: Placebo Placebo matched to Tralokinumab will be administered subcutaneously to participants once every 2 Weeks (Q2W) for 12 weeks. | Other: Placebo Subcutaneous injection with placebo |
Experimental: Tralokinumab Dose 1 Tralokinumab Dose 1 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks. | Biological/Vaccine: Tralokinumab Dose 1 Subcutaneous injection with tralokinumab |
Experimental: Tralokinumab Dose 2 Tralokinumab Dose 2 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks. | Biological/Vaccine: Tralokinumab Dose 2 Subcutaneous injection with tralokinumab |
Experimental: Tralokinumab Dose 3 Tralokinumab Dose 3 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks. | Biological/Vaccine: Tralokinumab Dose 3 Subcutaneous injection with tralokinumab |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.